Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen

Conclusions: A primary personalized cardioprotection strategy decreases the number of cardiac deaths and may potentially prolong overall survival in NHL patients with increased risk of anthracycline cardiotoxicity.Chemotherapy 2018;63:238 –245
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
Conclusion: Development of a fragmented QRS pattern in response to cancer therapy emerges as a new parameter potentially predictive of chemotherapy-induced cardiotoxicity.Oncol Res Treat
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
Background: Incidence of diffuse large B cell lymphoma (DLBCL), an aggressive but curable Non-Hodgkin Lymphoma (NHL) is increasing in the oldest old. Treatment of these patients is challenging due to advanced age, concomitant comorbidities present in this population and the paucity of data from this population in clinical trials.Aims: to evaluate which parameters are considered by medical oncologists in the management and systemic treatment of DLBCL in the oldest old patients (³80 years old) in our centers.Method: This retrospective study evaluated the management of 118 patients ³80 years old diagnosed with DLBCL...
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster III Source Type: research
Introduction. Recent research in lymphoma has resulted in better outcomes for clinical trial populations. Population studies have suggested that some real-world patients (pts) have not benefited. We hypothesized that one reason for this discrepancy is the difference between trial participants and real-world pts. We aimed to: 1) Compare demographics and baseline clinical characteristics of real-world and clinical trial pts receiving first-line therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL); and 2) Compare demographics and baseline clinical characteristics of real-...
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster II Source Type: research
ConclusionsThe long-term overall survival of the patients treated on S0816 remains high (94%) at 5 years. Despite historical data suggesting favorable clinical outcomes in patients with a negative PET2, nearly 25% of these patients experienced relapse events, demonstrating limitations of a PET-adapted approach and of standard frontline therapy with ABVD. In patients who were PET2+, PFS was favorable relative to historical series, but was associated with a high rate of secondary malignancies. Our results emphasize the importance of long-term follow-up in this disease, and the need for better biomarkers at diagnosis of HL an...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches Source Type: research
Conclusions. In this retrospective large US inpatient database analysis, we found that average rates of VTE in patients with hematologic malignancies was 5.3% and was highest in patients with AML. Patients receiving chemotherapy had highest risk of developing VTE during hospitalization followed by patients with infections such as sepsis and pneumonia. Higher rates of VTE in patients receiving chemotherapy and patients with sepsis was previously described, however our findings indicate that rate of VTE remain high in these population. Findings of our study can be used for development of the appropriate antithrombotic prophy...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Poster I Source Type: research
AbstractThe cardiotoxicity of chemotherapy (CTx) for non-Hodgkin ’s lymphomas is not well recognized. In order to facilitate individual risk counseling for patients, we analyzed the effect of CTx on echocardiographic indices in regard to clinical data in patients treated for non-Hodgkin’s lymphoma (NHL). A prospective multicenter ONCO-ECHO trial included 67 p atients with NHL (45 patients with DLBCL (diffuse large B cell lymphoma) and 22 with non-DLBCL). Patients received standard CTx, primarily R-CHOP, CHOP, R-COP and COP regimens. Clinical data and echocardiographic indices were obtained at baseline, 3-, 6- a...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Cancer therapeutics –related cardiac dysfunction induced by anthracycline is highly problematic, and its early recognition is of importance. Atrial fibrillation (AF) is sometimes seen after anthracycline chemotherapy. We aimed to test whether new-onset AF predicts anthracycline-induced heart failure. We prospectively studied 249 lymphoma patients who received anthracyclines. The patients were followed up with a frequent electrocardiographic examination. Fifteen (6%) patients newly developed AF after the chemotherapy, and during a mean follow-up of 34 months they had a higher incidence of acute heart failure (40 % vs.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
We report a case of lymphomatous pericarditis in the evolution of a non-Hodgkin's lymphoma, diagnosed by PET-CT scan, and occurring concomitantly with complete isotopic remission of enlarged mediastinal lymph nodes following chemotherapy. PMID: 26407332 [PubMed - as supplied by publisher]
Source: Cardiovascular Journal of Africa - Category: Cardiology Authors: Tags: Cardiovasc J Afr Source Type: research
00:00 to 02.26—Dr. Bihari gives his background and credentials. Dr. Bihari: My medical training started at Harvard Medical School. I graduated in 1957. Then I trained in Internal Medicine at one of the Harvard teaching hospitals in Boston, Beth Israel, and then in Neurology at Massachusetts General in Boston. Then I went to the National Institutes of Health for two years doing brain physiology—brain research. I did another residency training in Psychiatry in New York, at Columbia Presbyterian Medical Center and then, over the following five or six years, I got very involved in working in Drug Addiction. By 197...
Source: HONEST MEDICINE: My Dream for the Future - Category: Consumer Health News Authors: Tags: Anecdotal Treatments HONEST MEDICINE Integrative Medicine Low Dose Naltrexone Obituaries Source Type: blogs
More News: Bisoprolol | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Heart | Heart Failure | History of Medicine | Lymphoma | Non-Hodgkin's Lymphoma | Study